137 related articles for article (PubMed ID: 15108188)
1. Association between cytochrome P450 2D6 genotype and harm avoidance.
Roberts RL; Luty SE; Mulder RT; Joyce PR; Kennedy MA
Am J Med Genet B Neuropsychiatr Genet; 2004 May; 127B(1):90-3. PubMed ID: 15108188
[TBL] [Abstract][Full Text] [Related]
2. No association between CYP2D6 polymorphisms and personality trait in Japanese.
Iwashima K; Yasui-Furukori N; Kaneda A; Saito M; Nakagami T; Sato Y; Kaneko S
Br J Clin Pharmacol; 2007 Jul; 64(1):96-9. PubMed ID: 17324244
[TBL] [Abstract][Full Text] [Related]
3. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.
Peñas-LLedó EM; Dorado P; Pacheco R; González I; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1111-20. PubMed ID: 19604084
[TBL] [Abstract][Full Text] [Related]
4. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 polymorphism and character traits.
Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
[TBL] [Abstract][Full Text] [Related]
7. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
[TBL] [Abstract][Full Text] [Related]
8. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
Lindskov Krog P; Osterberg O; Gundorf Drewes P; Rembratt Å; Schultz A; Timmer W
Eur J Drug Metab Pharmacokinet; 2013 Mar; 38(1):43-51. PubMed ID: 22948856
[TBL] [Abstract][Full Text] [Related]
10. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
Bijl MJ; Visser LE; Hofman A; Vulto AG; van Gelder T; Stricker BH; van Schaik RH
Br J Clin Pharmacol; 2008 Apr; 65(4):558-64. PubMed ID: 18070221
[TBL] [Abstract][Full Text] [Related]
11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
13. Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations.
Elmokadem A; Bruno CD; Housand C; Jordie EB; Chow CR; Lesko LJ; Greenblatt DJ
J Clin Pharmacol; 2022 Jan; 62(1):66-75. PubMed ID: 34328221
[TBL] [Abstract][Full Text] [Related]
14. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Zawertailo LA; Kaplan HL; Busto UE; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
[TBL] [Abstract][Full Text] [Related]
15. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
16. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
[TBL] [Abstract][Full Text] [Related]
17. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
18. [Personality factors in depressive disorders: contribution of the psychobiologic model developed by Cloninger].
Pelissolo A; Corruble E
Encephale; 2002; 28(4):363-73. PubMed ID: 12232546
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
20. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4.
Monek O; Paintaud G; Bechtel Y; Miguet JP; Mantion G; Bechtel PR
Eur J Clin Pharmacol; 1998 Mar; 54(1):47-52. PubMed ID: 9591930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]